University of Alberta

Edmonton, Alberta, CA

Comprehensive public research university in Edmonton, Canada, with co-located labs, pilot facilities, hospital integration, co-op pipelines, and dedicated tech transfer. Regional industry clusters and provincial partners streamline collaboration.

The University of Alberta is a large, comprehensive public research university in Edmonton with multiple campuses and a strong applied research culture. Industry engages through co-located labs and pilot-scale facilities, as well as established co-op and internship programs that place talent with partners year-round. Integration with Alberta’s province-wide hospital system supports clinical research and accelerates translation. Companies also benefit from proximity to regional industry clusters and collaboration hubs on and near campus for joint R&D and prototyping. Supported by NSERC, CIHR, SSHRC, and Canada Foundation for Innovation funding—plus provincial and industry support—the tech transfer office manages IP, licensing, and startup formation with streamlined sponsored-research agreements.

Top industry applications

Halo’s AI pipeline combines publication data and faculty input to determine the industry applications with greatest concentration of publishing faculty. It then surfaces those with the strongest industry collaboration evidence.

Medicine

Medical diagnostics

University of Alberta researchers are advancing AI-driven diagnostic imaging and clinical decision-support tools that detect cancers, cardiac defects, and stroke risk with greater speed and accuracy. They are also developing portable biosensors—including surface-enhanced Raman spectroscopy platforms and at-home metabolite assays—that enable rapid, point-of-care monitoring of chronic kidney disease, gout, and metabolic disorders. Together, these innovations address critical gaps in emergency medicine, pathology, and rural healthcare access while offering strong commercial potential for scalable, cost-effective diagnostic technologies.

Medicine

Pharmaceuticals and drug delivery

University of Alberta researchers engineer advanced drug delivery systems—from lipid nanoparticles and inhalable powders to targeted hydrogels—to improve therapeutic outcomes in cancer, rare genetic disorders, and infectious disease. Their pharmaceutical pipeline combines AI-driven drug design, novel antisense and PROTAC modalities, and first-in-human clinical trials with pharmacogenetic and real-world evidence strategies. This work directly addresses industry demand for precision medicine platforms and commercially viable translational therapies.

Medicine

Medical imaging

University of Alberta researchers are embedding artificial intelligence across MRI, PET/CT, and ultrasound to automate segmentation, suppress noise, and sharpen diagnostics for cancer, heart disease, and pediatric conditions. Key outputs include AI-driven cardiac CT risk scores, point-of-care ultrasound for infant hip dysplasia and bone imaging, and novel brain MRI biomarkers for multiple sclerosis and dementia. By targeting radiology workflow gaps and screening bottlenecks, this work is advancing commercially viable tools for rapid, high-precision clinical decision-making.

Medicine

Oncology & cancer therapeutics

University of Alberta researchers are advancing first-in-human cancer drugs, including microtubule disruptors, antibody-drug conjugates, and siRNA-loaded nanoparticles that attack resistant leukemias and solid tumors. They are pioneering precision diagnostics—such as AI-driven pathology, PSMA theranostics, and spatial immune profiling—to personalize radiotherapy, immunotherapy, and drug combinations. Complementary trials target chemotherapy cardiotoxicity, cancer cachexia, and survivor quality of life through structured exercise and nutritional interventions.

Digital & computing technologies

Artificial intelligence & machine learning

University of Alberta teams are translating AI and machine learning research into high-impact solutions for healthcare, energy, and infrastructure. Their work includes clinical documentation tools, diagnostic imaging AI, and molecular design platforms that reduce costs and improve outcomes in medicine, alongside predictive maintenance and digital-twin technologies for pipelines and power systems. These applied innovations offer direct commercialization pathways for health technology, industrial automation, and environmental monitoring markets.

Energy & natural resources

Natural resource extraction

University of Alberta researchers advance bitumen extraction, tailings management, and low-carbon recovery technologies for the oil sands through the Institute for Oil Sands Innovation (IOSI), tackling the sector's core efficiency and environmental challenges. IOSI is anchored by a multi-year partnership with Imperial Oil—majority-owned by ExxonMobil—and Alberta Innovates, and its work feeds directly into industry consortia including COSIA and the Pathways Alliance. This makes the institution the primary academic R&D partner for a globally significant resource industry navigating decarbonization, giving energy companies structured access to extraction and remediation expertise.

Agriculture

Plant breeding and genetics

University of Alberta researchers breed improved wheat and canola cultivars using field genetics, marker-assisted selection, and disease-resistance trait development suited to western Canadian growing conditions. The canola program runs a named NSERC Alliance partnership with Bayer Crop Science, while the wheat program has commercialized fourteen varieties—including CS Tracker, CS Jake, and Parata—now grown across the Prairies through seed partners Canterra Seeds and SeCan. This track record of registered, farmer-adopted cultivars gives seed companies and grower commissions a proven pipeline from genetic discovery to commercial variety, anchoring the institution in Canada's multi-billion-dollar crop economy.

Medicine

Cardiovascular health

University of Alberta researchers are developing novel cardiovascular drugs, from apelin analogs that reverse severe pulmonary hypertension to ketone therapies that protect the heart during weight-loss treatment, filling critical gaps in heart failure and acute coronary care. They are also commercializing AI-powered cardiac monitoring and radar-based blood pressure tools while translating findings into clinical guidelines for hypertension and stroke prevention. This portfolio offers direct pathways for pharmaceutical, medical device, and digital health partnerships.

Last updated by Halo AI Sep 15, 2026. Please verify key information.

OpenAlex

For general inquiries

Joanna Preston

University Administrator, University of Alberta

Have a specific need?
Post a free request to University of Alberta faculty.

Top industry applications

Medical diagnosticsPharmaceuticals and drug deliveryMedical imagingOncology & cancer therapeuticsArtificial intelligence & machine learningNatural resource extractionPlant breeding and geneticsCardiovascular health